Pre-Emptive Rituximab Treatment for Epstein\textendashBarr Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation Is a Worthwhile Strategy in High-Risk Recipients: A Comparative Study for Immune Recovery and Clinical Outcomes - Sorbonne Université Access content directly
Journal Articles Bone Marrow Transplantation Year : 2020

Pre-Emptive Rituximab Treatment for Epstein\textendashBarr Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation Is a Worthwhile Strategy in High-Risk Recipients: A Comparative Study for Immune Recovery and Clinical Outcomes

Dates and versions

hal-03886732 , version 1 (06-12-2022)

Identifiers

Cite

Nicolas Stocker, Myriam Labopin, Inès Boussen, Olivier Paccoud, Agnès Bonnin, et al.. Pre-Emptive Rituximab Treatment for Epstein\textendashBarr Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation Is a Worthwhile Strategy in High-Risk Recipients: A Comparative Study for Immune Recovery and Clinical Outcomes. Bone Marrow Transplantation, 2020, 55 (3), pp.586--594. ⟨10.1038/s41409-019-0699-6⟩. ⟨hal-03886732⟩
7 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More